S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
TSE:GUD

Knight Therapeutics Stock Forecast, Price & News

C$5.15
+0.10 (+1.98 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.95
Now: C$5.15
C$5.15
50-Day Range
C$5.02
MA: C$5.44
C$5.69
52-Week Range
C$4.73
Now: C$5.15
C$8.08
Volume448,288 shs
Average Volume336,081 shs
Market CapitalizationC$671.28 million
P/E Ratio25.88
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Knight Therapeutics logo

Headlines

Why Knight Therapeutics' (TSE:GUD) CEO Pay Matters
August 18, 2020 |  finance.yahoo.com
Knight Therapeutics Reports Second Quarter 2020 Results
August 13, 2020 |  finance.yahoo.com
Profound Medical: The Prostate Market Disruptor
April 22, 2020 |  seekingalpha.com
Knight Announces the Re-Launch of Trelstar® in Canada
April 20, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-484-4483
Employees27
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$181.60 million
Cash FlowC$3.00 per share
Book ValueC$6.77 per share

Profitability

Miscellaneous

Market CapC$671.28 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.98 out of 5 stars

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
C$5.15
+0.10 (+1.98 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GUD News and Ratings via Email

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Knight Therapeutics (TSE:GUD) Frequently Asked Questions

Is Knight Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Knight Therapeutics stock.
View analyst ratings for Knight Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Knight Therapeutics?

Wall Street analysts have given Knight Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Knight Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Knight Therapeutics
.

How has Knight Therapeutics' stock price been impacted by COVID-19?

Knight Therapeutics' stock was trading at C$6.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GUD stock has decreased by 14.7% and is now trading at C$5.15.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GUD?

4 Wall Street analysts have issued 12-month price targets for Knight Therapeutics' shares. Their forecasts range from C$6.75 to C$8.00. On average, they anticipate Knight Therapeutics' stock price to reach C$7.56 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts' price targets for Knight Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the following people:
  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA, Founder, CEO & Director (Age 52, Pay $607.95k)
  • Ms. Samira Sakhia BCom, MBA, CPA, CA, Pres & Director (Age 53, Pay $616.21k)
  • Mr. Arvind Utchanah, Chief Financial Officer
  • Ms. Amal Khouri M.B.A., VP of Bus. Devel.
  • Ms. Jody Engel, Sr. Director of Bus. Devel.
  • Mr. Michel Loustric, Pres of Knight Barbados

Who are some of Knight Therapeutics' key competitors?

What other stocks do shareholders of Knight Therapeutics own?

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$5.15.

How much money does Knight Therapeutics make?

Knight Therapeutics has a market capitalization of C$671.28 million and generates C$181.60 million in revenue each year.

How many employees does Knight Therapeutics have?

Knight Therapeutics employs 27 workers across the globe.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is www.gud-knight.com.

How can I contact Knight Therapeutics?

The company can be reached via phone at 514-484-4483.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.